Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Hoos, C. Cordon-Cardo (2001)
Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and LimitationsLaboratory Investigation, 81
J. Ross, J. Ross, J. Fletcher, G. Linette, G. Linette, J. Stec, E. Clark, M. Ayers, W. Symmans, L. Pusztai, K. Bloom (2003)
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.The oncologist, 8 4
M. Coombes, Emma Ph.D., Lorna Ph.D., Robert M.Phil., Ph.D Jassem, Thierry Ph.D., Stephen M.D., Isabel M.D., M. Bertelli, Olaf M.D., Alan Ph.D., Emilio M.D., David M.D., M. Coleman, Lesley M.D., D.Phil, M. Mickiewicz, D.M.Sc Andersen, Per Lønning, Giorgio Ph.D., Alan Ph.D., Nick M.D., M.Sc Snowdon, Ph.D Carpentieri, M. Massimini, M.Sc Bliss (1977)
THE NEW ENGLAND JOURNAL OF MEDICINEThe Lancet, 309
R. Camp, L. Charette, D. Rimm (2000)
Validation of Tissue Microarray Technology in Breast CarcinomaLaboratory Investigation, 80
R. Ridolfi, M. Jamehdor, J. Arber (2000)
HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization ApproachModern Pathology, 13
(2001)
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent false-positives do not get the message
M. Skacel, Bradley Skilton, J. Pettay, R. Tubbs (2002)
Tissue Microarrays: A Powerful Tool for High-Throughput Analysis of Clinical Specimens: A Review of the Method With Validation DataApplied Immunohistochemistry & Molecular Morphology, 10
M. Tanner, D. Gancberg, A. Leo, D. Larsimont, G. Rouas, M. Piccart, J. Isola (2000)
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.The American journal of pathology, 157 5
(2003)
Recommendations for HER2 testing
Kyeongmee Park, Jungyeon Kim, Sungjig Lim, Sehwan Han, Jung Lee (2003)
Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2/neu Status in Primary Breast Carcinoma using Tissue MicroarrayModern Pathology, 16
J. Zujewski (2002)
"Build quality in"--HER2 testing in the real world.Journal of the National Cancer Institute, 94 11
(2003)
The HER-2/neu gene in breast cancer 2003: biomarker and target of therapy
I. Bukholm, G. Bukholm, R. Holm, J. Nesland (2003)
Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomasJournal of Clinical Pathology, 56
T. Jacobs, A. Gown, H. Yaziji, Melissa Barnes, S. Schnitt (1999)
Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
B. Leyland-Jones (2002)
Trastuzumab: hopes and realities.The Lancet. Oncology, 3 3
J. Isola, L. Chu, S. Devries, K. Matsumura, K. Chew, B. Ljung, F. Waldman (1999)
Genetic alterations in ERBB2-amplified breast carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 12
G. Pauletti, Suganda Dandekar, H. Rong, Lilllian Ramos, Hongjun Peng, Ram Seshadri, D. Slamon (2000)
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 21
A. O'Grady, Claire Flahavan, E. Kay, H. Barrett, M. Leader (2003)
HER-2 Analysis in Tissue Microarrays of Archival Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ HybridizationApplied Immunohistochemistry & Molecular Morphology, 11
Sijian Wang, M. Saboorian, Eugene Frenkel, Barbara Haley, M. Siddiqui, S. Gokaslan, L. Hynan, R. Ashfaq (2002)
Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu StatusModern Pathology, 15
J. Kononen, L. Bubendorf, Anne Kallionimeni, M. Bärlund, P. Schraml, S. Leighton, J. Torhorst, M. Mihatsch, G. Sauter, Olli-P. Kallionimeni (1998)
Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 4
R. Jimenez, T. Wallis, Pam Tabasczka, D. Visscher (2000)
Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationModern Pathology, 13
M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau, A. Moreno, F. Penault-Llorca, J. Rüschoff, G. Tomasic, M. Vijver (2003)
Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesModern Pathology, 16
P. Lal, Paulo Salazar, M. Ladanyi, Beiyun Chen (2003)
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.The Journal of molecular diagnostics : JMD, 5 3
Tubbs Rr, J. Pettay, P. Roche, M. Stoler, R. Jenkins, T. Grogan (2001)
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
S. Mccormick, T. Lillemoe, J. Beneke, J. Schrauth, J. Reinartz (2002)
HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.American journal of clinical pathology, 117 6
M. Mengel, H. Kreipe, R. Wasielewski (2003)
Rapid and Large-Scale Transition of New Tumor Biomarkers to Clinical Biopsy Material by Innovative Tissue Microarray SystemsApplied Immunohistochemistry & Molecular Morphology, 11
Jianxin Zhao, R. Wu, A. Au, A. Marquez, Yibing Yu, Zuorong Shi (2002)
Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast CarcinomaModern Pathology, 15
S. Bose, M. Mohammed, P. Shintaku, P. Rao (2001)
Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu PolysomyThe Breast Journal, 7
TECHNICAL HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization Pequita Loring, BSc, Robert Cummins, BSc, Anthony O’Grady, MSc, and Elaine W. Kay, FRCPath a target-specific therapy that acts by inhibiting tyrosine kinase Abstract: An accurate and reproducible assay method for determin- 1,2 activity. Currently practiced laboratory methods for HER2 ing HER2 status is crucial, as a positive HER2 gene status is an eli- assessment include immunohistochemical (IHC) methods gibility requirement for Herceptin™ therapy. Although immunohis- (measuring increased protein expression) and fluorescence in tochemical (IHC) assessment is both practical and inexpensive, a Situ hybridization (FISH) and chromogenic in situ hybridiza- worrying trend of high false-positive rates has been reported. Fluo- 1,3 tion (CISH) (both measuring gene amplification). rescence in situ hybridization (FISH) is the universally accepted gold standard for confirming IHC 2+ cases and ambiguous results but is IHC assessment of HER2 neu status is practical, inex- costly and requires specialized equipment and technical expertise. pensive, familiar, and easily automated and is therefore the Chromogenic in situ hybridization (CISH) amalgamates the practical most commonly applied method used in
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jun 1, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.